Evaxion Biotech A/S

NasdaqCM EVAX

Evaxion Biotech A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 10.69 M

Evaxion Biotech A/S Net Cash Used Provided By Financing Activities is USD 10.69 M for the year ending December 31, 2023, a 36.14% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Evaxion Biotech A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 7.85 M, a -84.23% change year over year.
Evaxion Biotech A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 49.80 M, a 464.81% change year over year.
Evaxion Biotech A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 8.82 M, a -7.26% change year over year.
Evaxion Biotech A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 9.51 M, a 5.33% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: EVAX

Evaxion Biotech A/S

CEO	Mr. Christian Kanstrup M.Sc.
IPO Date	Feb. 5, 2021
Location	Denmark
Headquarters	Dr. Neergaards Vej
Employees	49
Sector	Healthcare
Industries Biotechnology Vaccines

Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Key trends

Past 5 years